Literature DB >> 12091282

Monitoring cardiovascular function in infants with chronic lung disease of prematurity.

S H Abman1.   

Abstract

In addition to persistent airways disease, survivors of premature birth with chronic lung disease are at risk of cardiovascular sequelae, including pulmonary hypertension, systemic hypertension, left ventricular hypertrophy, and exercise intolerance. The major treatment of pulmonary hypertension is supplemental oxygen, but drugs such as calcium channel blockers may also be required. The use of inhaled nitric oxide for its long term management is being investigated

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12091282      PMCID： PMC1721426          DOI： 10.1136/fn.87.1.f15

Source DB:  PubMed          Journal:  Arch Dis Child Fetal Neonatal Ed        ISSN： 1359-2998            Impact factor:   5.747


  20 in total

1.  Bronchopulmonary dysplasia.

Authors:  A H Jobe; E Bancalari
Journal:  Am J Respir Crit Care Med       Date:  2001-06       Impact factor: 21.405

2.  Persistent pulmonary hypertension in premature neonates with severe respiratory distress syndrome.

Authors:  F J Walther; M J Benders; J O Leighton
Journal:  Pediatrics       Date:  1992-12       Impact factor: 7.124

3.  Reduced gas transfer at rest and during exercise in school-age survivors of bronchopulmonary dysplasia.

Authors:  S H Mitchell; W G Teague
Journal:  Am J Respir Crit Care Med       Date:  1998-05       Impact factor: 21.405

4.  Inhaled nitric oxide in premature neonates with severe hypoxaemic respiratory failure: a randomised controlled trial.

Authors:  J P Kinsella; W F Walsh; C L Bose; D R Gerstmann; J J Labella; S Sardesai; M C Walsh-Sukys; M J McCaffrey; D N Cornfield; V K Bhutani; G R Cutter; M Baier; S H Abman
Journal:  Lancet       Date:  1999-09-25       Impact factor: 79.321

5.  Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia.

Authors:  W H Northway; R C Rosan; D Y Porter
Journal:  N Engl J Med       Date:  1967-02-16       Impact factor: 91.245

6.  Value of echocardiography in assessing the outcome of bronchopulmonary dysplasia of the newborn.

Authors:  J C Fouron; J C Le Guennec; D Villemant; G Perreault; A Davignon
Journal:  Pediatrics       Date:  1980-03       Impact factor: 7.124

7.  Effects of inhaled nitric oxide on pulmonary edema and lung neutrophil accumulation in severe experimental hyaline membrane disease.

Authors:  J P Kinsella; T A Parker; H Galan; B C Sheridan; A C Halbower; S H Abman
Journal:  Pediatr Res       Date:  1997-04       Impact factor: 3.756

8.  Changes in oxygenation with inhaled nitric oxide in severe bronchopulmonary dysplasia.

Authors:  B A Banks; I Seri; H Ischiropoulos; J Merrill; J Rychik; R A Ballard
Journal:  Pediatrics       Date:  1999-03       Impact factor: 7.124

9.  Pulmonary vascular extraction of circulating norepinephrine in infants with bronchopulmonary dysplasia.

Authors:  S H Abman; M S Schaffer; J Wiggins; R Washington; M Manco-Johnson; R R Wolfe
Journal:  Pediatr Pulmonol       Date:  1987 Nov-Dec

10.  Pathology of arrested acinar development in postsurfactant bronchopulmonary dysplasia.

Authors:  A N Husain; N H Siddiqui; J T Stocker
Journal:  Hum Pathol       Date:  1998-07       Impact factor: 3.466
View more
  24 in total

Review 1.  Frontiers in pulmonary hypertension in infants and children with bronchopulmonary dysplasia.

Authors:  Joseph M Collaco; Lewis H Romer; Bridget D Stuart; John D Coulson; Allen D Everett; Edward E Lawson; Joel I Brenner; Anna T Brown; Melanie K Nies; Priya Sekar; Lawrence M Nogee; Sharon A McGrath-Morrow
Journal:  Pediatr Pulmonol       Date:  2012-07-06

2.  Excess soluble vascular endothelial growth factor receptor-1 in amniotic fluid impairs lung growth in rats: linking preeclampsia with bronchopulmonary dysplasia.

Authors:  Jen-Ruey Tang; S Ananth Karumanchi; Gregory Seedorf; Neil Markham; Steven H Abman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-10-14       Impact factor: 5.464

3.  Inhaled nitric oxide and oral nifedipine in a preterm infant with bronchopulmonary dysplasia and pulmonary hypertension.

Authors:  Enrico Rosati; Gianfranco Butera; Eduardo Bossone; Claudio De Felice; Giuseppe Latini
Journal:  Eur J Pediatr       Date:  2006-11-14       Impact factor: 3.183

4.  Prospective analysis of pulmonary hypertension in extremely low birth weight infants.

Authors:  Ramachandra Bhat; Ariel A Salas; Chris Foster; Waldemar A Carlo; Namasivayam Ambalavanan
Journal:  Pediatrics       Date:  2012-02-06       Impact factor: 7.124

5.  Combined l-citrulline and tetrahydrobiopterin therapy improves NO signaling and ameliorates chronic hypoxia-induced pulmonary hypertension in newborn pigs.

Authors:  Anna Dikalova; Judy L Aschner; Mark R Kaplowitz; Gary Cunningham; Marshall Summar; Candice D Fike
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-02-19       Impact factor: 5.464

Review 6.  Skeletal dysplasia: Respiratory management during infancy.

Authors:  Deepthi Alapati; Thomas H Shaffer
Journal:  Respir Med       Date:  2017-08-01       Impact factor: 3.415

7.  Looking beyond PPHN: the unmet challenge of chronic progressive pulmonary hypertension in the newborn.

Authors:  Candice D Fike; Judy L Aschner
Journal:  Pulm Circ       Date:  2013-11-19       Impact factor: 3.017

8.  Antenatal and postnatal risk factors for neonatal hypertension and infant follow-up.

Authors:  Wael A Seliem; Michael C Falk; Bruce Shadbolt; Alison L Kent
Journal:  Pediatr Nephrol       Date:  2007-09-14       Impact factor: 3.714

9.  Reactive oxygen species-reducing strategies improve pulmonary arterial responses to nitric oxide in piglets with chronic hypoxia-induced pulmonary hypertension.

Authors:  Candice D Fike; Anna Dikalova; James C Slaughter; M R Kaplowitz; Y Zhang; Judy L Aschner
Journal:  Antioxid Redox Signal       Date:  2013-01-29       Impact factor: 8.401

10.  Use of inhaled iloprost in an infant with bronchopulmonary dysplasia and pulmonary artery hypertension.

Authors:  Seung-Kyung Hwang; Yung-Chul O; Nam-Su Kim; Hyun-Kyung Park; Myung-Kul Yum
Journal:  Korean Circ J       Date:  2009-08-27       Impact factor: 3.243
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.